Pelargonium sidoides DC (Geraniacea) is a medicinal plant indigenous to Southern Africa that has been widely evaluated for its use in the treatment of upper respiratory tract infections. In recent studies, the anti-proliferative potential of P. sidoides was shown and several phenolic compounds were identified as the bioactive compounds. Little, however, is known regarding their anti-proliferative protein targets. In this study, the anti-proliferative mechanisms of P. sidoides through in silico target identification and network pharmacology methodologies were evaluated. The protein targets of the 12 phenolic compounds were identified using the target-identification server PharmMapper and the server for predicting Drug Repositioning and Adverse Reactions via the Chemical-Protein Interactome (DRAR-CPI). Protein-protein and protein-pathway interaction networks were subsequently constructed with Cytoscape 3.4.0 to evaluate potential mechanisms of action. A total of 142 potential human target proteins were identified with the in silico target identification servers and 90 of these were found to be related to cancer. The protein interaction network was constructed from 86 proteins involved in 209 interactions with each other, and two protein clusters were observed. A pathway enrichment analysis identified over 80 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched with the protein targets and included several pathways specifically related to cancer as well as various signaling pathways that have been found to be dysregulated in cancer. These results indicate that the anti-proliferative activity of P. sidoides may be multifactorial and arises from the collective regulation of several interconnected cell signaling pathways.
Introduction
(PFKFB1), PTPN1, uridine-cytidine kinase 2 (UCK2).
The DRAR-CPI server revealed another 97 different potential human protein targets with a cutoff docking score of -50.000 and z-score values smaller than -1.5. As observed with the PharmMapper server, some of the protein targets identified were found to be potential targets of more than one compound. This was observed for 35 different protein targets.
Some protein targets were also shared between the two servers as seen with 67DiOHC8S and target CBS, PGS and glutathione S-transferase A1 (GSTA1) as well as target PTPN1 and potential inhibitors PLMF1 and 67DiOHC8S. Taken collectively, 142 different human proteins were found to be potential targets of the 12 compounds (Fig. 1 ). PLMF1 and PGS were found to be the least selective with 49 and 47 potential targets, respectively. Both have a sulfated sugar moiety that may play an important role in forming intermolecular hydrogen bonds with the active site of the target proteins. On the other hand, the GCGCGC trimer, gallic acid and 678TriOHC were found to be most selective with three, five and four potential targets, respectively. The GCGCGC trimer has a very large and bulky structure and this likely limits its access to the protein's active site while for gallic acid and 678TriOHC, their relatively small structures with only a few hydrogen bond donors and acceptors likely limits their interactions with the protein's active site. It was observed that similar structures shared similar potential protein targets, and this could be seen from PLMF1 and PGS that shared 20 protein targets, LMF2 and LMF3 shared five, the two dihydroxycoumarin sulfates shared eight while the proanthocyanidin dimers shared four. Of the 142 potential human target proteins that were identified with the in silico target fishing servers, 90 were found to be related to cancer, based on literature sources as well as the Disease and Gene Database (Fig. 1) . These in silico results provide support for the observed anti-proliferative activity of P. sidoides with in vitro studies. 
Protein interaction network and pathway enrichment analysis
In order to explore where these protein targets may play a role, a protein interaction network as well as pathway enrichment analysis were performed [35] . The protein interaction network in Fig. 2 was constructed with the String Database using the highest confidence score (0.900) and excluding all isolated nodes. Within this protein interaction network, two large clusters connected by glutathione S-transferase P (GSTP1) were observed. These clusters suggest that the bioactive compounds of P. sidoides are targeting proteins that are either part of the same protein complex or involved in the same pathway [47] . Several signaling pathways were also identified and some of these pathways have been found to be dysregulated in cancer as has been observed with the ErbB, vascular endothelial growth factor (VEGF), mitogen-activated protein kinase (MAPK), Ras, phosphatidylinositol-3-kinase (PI3K)-Akt, Rap1, 5'-adenosine monophosphate-activated protein kinase (AMPK), Wnt, focal adhesion, hypoxia inducible factor (HIF-1) and mammalian target of rapamycin (mTOR) signaling pathways [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] . Dysregulation of these pathways has been found to be associated with increased cell proliferation, cell survival, inhibition of apoptosis, cell migration and invasion as well as angiogenesis. kinases, may also regulate these same pathways by scavenging the reactive oxygen and nitrogen species that can also activate these pathways.
The glutathione pathway (hsa00480) was also found to be enriched with an FDR of 1.36e-08, and it was not surprising that some of the compounds were found to be potential substrates of the GSTs. The GSTs are enzymes that conjugate glutathione to xenobiotics for detoxification [68] . Several anticancer drugs have been found to be substrates of the GSTs, and the GSTs have been implicated in chemotherapeutic drug resistance development. The P. sidoides compounds may thus through their interaction with the GSTs, deplete glutathione and reduce the excretion of these drugs thus prolonging their therapeutic effects. This depletion may be beneficial for drugs that have a short half-life but harmful if a drug has a long half-life as toxicity may then become a factor with the longer exposure times. Besides their role in detoxification pathways, the GSTs have been found to be upregulated in several cancer types and have been found to play a role in the regulation of the MAP kinase pathway by inhibiting JNK-induced apoptosis [68] . The P. sidoides compounds thus by targeting the GSTs may result in an anti-proliferative effect by preventing the GSTs from inhibiting JNK and allowing the cells to undergo stress-induced apoptosis. This speculation suggests that a combination therapy of P. sidoides extract with anti-cancer drugs may be particularly effective, by draining away glutathione, thus prolonging the half-life of the drugs, and inhibiting GSTs so that JNK-induced apoptosis of the cancer cells may proceed unhindered.
Also of particular interest, was that these pathways are activated by the inflammatory mediators, cytokines and growth factors, and extracts of P. sidoides has previously shown anti-inflammatory activity in vivo [14] . Besides inflammation, the protein targets and activation of these signaling pathways are also found to play important roles during innate immune responses to generate a defense to invading pathogens. P. sidoides extracts have also been found to exert immunomodulatory activity [6, 9, 10] . Table 2) .
The results presented here may thus also suggest the inflammatory pathways regulated by P. sidoides extracts as well as provide evidence for the immunomodulation associated with P. sidoides extracts. Also, the immune system has been shown to play an important role in cancer progression and drugs such as thalidomide and pomalidomide that can inhibit the action of some of the inflammatory mediators and enhance the activity of immune effectors have proven useful in the treatment of cancer [69] [70] [71] . Thus, the immunomodulatory activity of P. sidoides may also account for its anti-proliferative activity. The results of this study highlight not only the potential polypharmacological nature of the P.
sidoides compounds evaluated here but also the complexity of treating a disease like cancer. Cancer is a complex multi-step disease involving mutations and genomic instability leading to uncontrolled cell growth, resistance to cell death, angiogenesis, invasion, inflammation and immune evasion [72] . Over the years, drug discovery has moved from the idea of a "single drug single target" to a "single drug multiple targets" idea [73] [74] [75] . Although the polypharmacological nature of drug compounds may be viewed as an undesirable feature due to the possibility of adverse reactions, looking at the complexity of cancer as a disease this "single drug multiple targets" idea or "multiple drugs multiple targets" may be better suited to its therapeutic treatment. This is observed with the use of multi-kinase inhibitors like sunitinib, axitinib, lapatinib and sorafenib that target several protein kinases as well as combination therapy in cancer treatment strategies [74] .
The majority of the compounds evaluated here were predicted to have more than 10 potential protein targets, with the exception being gallic acid, the trihydroxycoumarin as well as the bulky GCGCGC proanthocyanin trimer. The main type of protein targets of these compounds were the protein kinases that were found to be involved in Ras-MAPK and PI3K-AKT signaling pathways (Fig. 4) . sidoides compounds) [57, 79] . Thus, the P. sidoides compounds besides inhibiting the growth of the tumor cells through regulation of the PI3K-AKT and Ras-MAPK pathways may also inhibit the process of angiogenesis through the attenuation of the PI3K-AKT and Ras-MAPK pathways in the cells of the vascular system. The VEGF signaling pathway (hsa04370) was found to be enriched for the protein targets of the P. sidoides compounds (Table 1) .
Similarly, the release of growth factors from the tumor cells can act on the surrounding cells of the extracellular matrix (ECM) like the fibroblasts and through the activation of the PI3K-AKT and Ras-MAPK pathways, promote their proliferation, survival, migration and subsequent ECM remodeling allowing for tumor migration [80] . Also, regulation of these two key pathways by the P. sidoides compounds should have an anti-inflammatory effect by inhibiting the release and production of inflammatory cytokines and growth factors from immune cells like the macrophages and neutrophils that are associated with the tumor microenvironment and drive tumorigenesis [62, 77] . This is evident from the immune related pathways that were found to be enriched with the PI3K-AKT and Ras-MAPK protein targets of the P. sidoides compounds (Table 2) .
Thus, through the collective regulation/inhibition of these protein targets by the bioactive compounds of P. sidoides that are involved in parallel and interlinked pathways and are important to several cell types found in the tumor microenvironment, a significant effect on not only tumor cell proliferation (as observed with our in vitro studies) but on the tumorigenesis process as a whole should be observed with in vivo studies. The P. sidoides compounds need not necessarily be strong binders of these protein targets but by potentially binding to and affecting the activity of multiple proteins and weakening their interactions with each other, the P. sidoides compounds should efficiently attenuate these signaling pathways resulting in reduced cancer cell proliferation, migration and evasion [73] . Also, by inhibiting several parallel signal transduction pathways, there may also be less of a chance of resistance development [74] . The polypharmacological nature of compounds and in particular phenolic compounds also suggest why these compounds show beneficial effects in the treatment of a wide variety of diseases. This is observed with green tea and its primary bioactive compounds the catechins that have been shown in previous studies to have beneficial effects in the prevention and treatment of diseases like cancer, Alzheimer's, cardiovascular diseases, diabetes and infections [35] .
Conclusions
In this study, in silico target identification coupled with network pharmacology have provided important insights into the anti-proliferative activity of P. sidoides and further provided support for the bioactivity observed in vitro. The major protein targets identified were shown to be protein kinases involved in signal transduction events particularly those concerned with the Ras/MAPK and PI3K-Akt signaling pathways that have been found to be dysregulated in cancer. The results also provided insight into the anti-inflammatory and immunomodulatory activity that has been found in vivo to be associated with P. sidoides extracts. These results suggest that the anti-proliferative activity of P. sidoides may be multifactorial and arises from the collective regulation of several interconnected cell signaling pathways. It remains to be seen whether further in vitro and in vivo studies will reflect the in silico results presented here.
